Story
Japanese Stocks to Refocus on Fundamentals by Year-End, Citi Says

Summary
Citi analysts predict that corporate fundamentals will once again become the primary driver for Japanese stock performance into the end of the year, following a third quarter dominated by thematic and macroeconomic factors.
Japanese equities are expected to pivot back toward fundamentals-driven performance by the end of the year, according to analysts at Citi, after a third quarter where such factors were largely ignored by the market.
A Quarter of Disconnect
In a recent note, the bank observed that Japanese stocks traded within a range from July through September, a period when fundamentals-related factors like earnings forecast revisions and EPS growth turned sharply negative. This marked a departure from the typical market behavior for this time of year, when investors usually focus more heavily on corporate results between first-quarter and first-half earnings seasons.
Citi attributed the third-quarter disconnect to several overriding thematic and macroeconomic pressures. The bank highlighted a combination of factors that temporarily overshadowed corporate earnings, including:
- The premature pricing-in and subsequent reversal of strong results for stocks in the AI and semiconductor sectors.
- A steepening yield curve.
- Rising crude oil prices.
AdOutlook: A Return to Fundamentals
Looking ahead, the firm anticipates these "one-off" factors will likely fade as the year concludes. This should allow the market to return to an environment where fundamentals regain their traditional influence on valuations.
Citi stated that the same fundamentals-related drivers that proved ineffective in the third quarter are expected to dictate share price performance once again in the Japanese equity market heading into year-end.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.